WO2021043953A1
|
|
Kinase activity signatures for predicting the response of non-small-cell lung carcinoma patients to a pd-1 or pd-l1 immune checkpoint inhibitor
|
EP3665301A1
|
|
Method for predicting the response of non-small-cell lung carcinoma patients to a medicament
|
WO2017167942A1
|
|
Method for predicting the response of melanoma patients to a medicament
|
EP3757223A1
|
|
Method for predicting the response of melanoma patients to a medicament
|
EP3298160A1
|
|
Method for predicting the response of melanoma patients to targeted pharmacotherapy
|
WO2016162451A1
|
|
A multi-layer cold specimen transport container without active cooling.
|
WO2014079927A1
|
|
Method and system for snap freezing tissues
|
WO2013037972A1
|
|
Method for predicting response to endocrine therapy
|
WO2012159997A1
|
|
Modified tyrosine amino acids, peptides containing them, and their use for detecting hydrolase enzyme activity
|
WO2012131065A1
|
|
Diagnosis, prognosis and treatment of scirrhous gastric cancer
|
WO2012049329A1
|
|
Method for predicting tyrosine kinase inhibitor (tki) resistance in patients suffering from chronic myelogenous leukemia (cml)
|
EP2417265A2
|
|
Method for predicting the response of locally advanced rectal cancer to chemoradiotherapy
|
EP2279262A2
|
|
Measurement of protein kinase activity in cerebrospinal fluid for diagnosis of neurological and psychiatric disorders
|
EP2243481A1
|
|
Irak kinase family as novel drug target for Alzheimer
|
EP2239570A1
|
|
Method for determining the estrogen receptor status of breast cancer
|
EP2239571A1
|
|
Method for profiling drug compounds using protein kinase inhibitors
|
EP2239578A1
|
|
Method for determining the survival prognosis of patients suffering from non-small cell lung cancer (NSCLC)
|
EP2239579A1
|
|
Method for the predicting of the response of non-small cell lung cancer patients to targeted pharmacotherapy
|
EP2239572A1
|
|
Method for the diagnosing and/or typing renal cell carcinoma
|
WO2009125020A1
|
|
Method for profiling drug compounds
|